Details of the Drug

General Information of Drug (ID: DMUM7HZ)

Drug Name

Fluorouracil

Synonyms

5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Biliary tract cancer	2C17	Approved	[1]
Colon adenocarcinoma	N.A.	Approved	[1]
Esophageal squamous cell carcinoma	2E60.1	Approved	[1]
Gastric intestinal type adenocarcinoma	N.A.	Approved	[1]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[1]
Metastasis from malignant tumor of colon	N.A.	Approved	[1]
Pancreatic adenocarcinoma	N.A.	Approved	[1]
Rectal adenocarcinoma	2B92	Approved	[1]
Rectum mucinous adenocarcinoma	N.A.	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Colon cancer	2B90.Z	Investigative	[1]
Colon mucinous adenocarcinoma	N.A.	Investigative	[1]
Colorectal cancer	2B91.Z	Investigative	[3]
Gastric cancer	2B72	Investigative	[1]
Tumour	2A00-2F9Z	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Immunosuppressive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

130.08

Logarithm of the Partition Coefficient (xlogp)

-0.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The absorption of drug is 28-100% []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 26 mL/min/kg [6]
Elimination: 5% of drug is excreted from urine in the unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 20 minutes [6]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 92.25 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.64% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.23 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 12.2 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Apoptosis	Not Available	CRMB1	OT06I7G2	[8]
Neutropenia	rs6740660	SERPINE2	OTYF5340	[9]
Neutropenia	rs6706693	OBFC2A	OTFTNFHW	[9]
-----------

Chemical Identifiers

Formula: C4H3FN2O2
IUPAC Name: 5-fluoro-1H-pyrimidine-2,4-dione
Canonical SMILES: C1=C(C(=O)NC(=O)N1)F
InChI: InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
InChIKey: GHASVSINZRGABV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3385
ChEBI ID: CHEBI:46345
CAS Number: 51-21-8
DrugBank ID: DB00544
TTD ID: D05LEO
VARIDT ID: DR00153
INTEDE ID: DR0020
ACDINA ID: D01095

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[10]
Dihydrothymine dehydrogenase (DPYD)	TTZPS91	DPYD_HUMAN	Inhibitor	[11]
TERT messenger RNA (TERT mRNA)	TTQY2EJ	TERT_HUMAN	Not Available	[4]
Thymidylate synthase messenger RNA (TYMS mRNA)	TTP1UKZ	TYSY_HUMAN	Not Available	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Equilibrative nucleoside transporter 1 (SLC29A1)	DTXD1TQ	S29A1_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 5 (ABCC5)	DTYVM24	MRP5_HUMAN	Substrate	[13]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[14]
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[13]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[15]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[13]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[16]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[18]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[18]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[18]
Thymidylate synthase (TYMS)	DEASG0Q	TYSY_HUMAN	Substrate	[19]
Methylenetetrahydrofolate reductase (MTHFR)	DEOXTPZ	MTHR_HUMAN	Substrate	[19]
Thymidine phosphorylase (TYMP)	DE4HCYL	TYPH_HUMAN	Substrate	[19]
Uridine phosphorylase 1 (UPP1)	DEFZWAX	UPP1_HUMAN	Substrate	[20]
Dihydrothymine dehydrogenase (DPYD)	DESOEW1	DPYD_HUMAN	Substrate	[21]
Uridine 5'-monophosphate synthase (UMPS)	DEWJYTE	UMPS_HUMAN	Substrate	[22]
Uracil phosphoribosyltransferase (UPRT)	DE20ETR	UPP_HUMAN	Substrate	[23]
Uridine phosphorylase 2 (UPP2)	DEBQ2WU	UPP2_HUMAN	Substrate	[20]
Amidophosphoribosyltransferase (GPAT)	DEMJ7R2	PUR1_HUMAN	Substrate	[24]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCG1)	OTSBQR6D	PLCG1_HUMAN	Drug Response	[25]
10 kDa heat shock protein, mitochondrial (HSPE1)	OT7JSZLB	CH10_HUMAN	Gene/Protein Processing	[26]
14-3-3 protein epsilon	OT3WQXNA	1433E_HUMAN	Gene/Protein Processing	[27]
14-3-3 protein eta	OTP8NJFJ	1433F_HUMAN	Drug Response	[28]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[29]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Gene/Protein Processing	[30]
2'-5'-oligoadenylate synthase 2 (OAS2)	OT64CCTM	OAS2_HUMAN	Gene/Protein Processing	[29]
2-oxoglutarate and iron-dependent oxygenase JMJD4 (JMJD4)	OTYZGH63	JMJD4_HUMAN	Gene/Protein Processing	[31]
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial (BCKDHA)	OT0LHOZB	ODBA_HUMAN	Gene/Protein Processing	[30]
28 kDa heat- and acid-stable phosphoprotein (PDAP1)	OTJSWMOD	HAP28_HUMAN	Gene/Protein Processing	[27]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluorouracil

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vinblastine	DM5TVS3	Minor	Decreased metabolism of Fluorouracil caused by Vinblastine mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
-----------

Coadministration of a Drug Treating the Disease Different from Fluorouracil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Fluorouracil and Roflumilast.	Asthma [CA23]	[33]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[34]
ABT-492	DMJFD2I	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[34]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Fluorouracil and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[35]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Fluorouracil and Denosumab.	Low bone mass disorder [FB83]	[36]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Fluorouracil and Porfimer Sodium.	Lung cancer [2C25]	[37]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Fluorouracil and Thalidomide.	Multiple myeloma [2A83]	[38]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Fluorouracil and Tecfidera.	Multiple sclerosis [8A40]	[39]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Fluorouracil and Siponimod.	Multiple sclerosis [8A40]	[40]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Fluorouracil and Fingolimod.	Multiple sclerosis [8A40]	[41]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Fluorouracil and Ocrelizumab.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Fluorouracil and Ozanimod.	Multiple sclerosis [8A40]	[33]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Fluorouracil and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[43]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[34]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Fluorouracil and Canakinumab.	Rheumatoid arthritis [FA20]	[44]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Fluorouracil and Rilonacept.	Rheumatoid arthritis [FA20]	[44]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Fluorouracil and Golimumab.	Rheumatoid arthritis [FA20]	[45]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Fluorouracil and Leflunomide.	Rheumatoid arthritis [FA20]	[35]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Fluorouracil when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[46]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Fluorouracil and Azathioprine.	Transplant rejection [NE84]	[40]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[34]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Fluorouracil due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[34]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Fluorouracil and Ganciclovir.	Virus infection [1A24-1D9Z]	[40]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Fluorouracil and Valganciclovir.	Virus infection [1A24-1D9Z]	[40]
-----------


⏷ Show the Full List of 30 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
methylparaben	E00149	7456	Antimicrobial preservative
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Trolamine	E00151	7618	Alkalizing agent; Emulsifying agent
Edetate disodium	E00186	8759	Complexing agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sorbitan monooleate	E00503	9920342	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Tromethamine	E00125	6503	Alkalizing agent; Buffering agent; Emulsifying agent
Water	E00035	962	Solvent
Ethylhexyl hydroxystearate	E00534	5463971	Emollient
Dimethicone 350	E00706	Not Available	Antifoaming agent; Emollient; Water-repelling agent
Methyl gluceth-20	E00708	62247	Emulsifying agent; Humectant
--------------------


⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fluorouracil 0.5% cream	0.50%	Cream	Topical
Fluorouracil 2% solution	2%	Solution	Topical
Fluorouracil 1g/20ml solution	1g/20ml	Solution	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Fluorouracil FDA Label
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
5	BDDCS applied to over 900 drugs
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
10	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
11	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
12	Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
13	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
14	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
15	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
16	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
17	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
18	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
19	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
20	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
21	5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.
22	Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis. 2016 Apr 5;4(1):e1165909.
23	Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000 Jul;7(7):1015-22.
24	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150653776)
25	Antitumour effects on human colorectal carcinomas cells by stable silencing of phospholipase C-gamma 1 with lentivirus-delivered siRNA. Chin Med J (Engl). 2007 May 5;120(9):749-54.
26	5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004 Mar-Apr;24(2A):417-23.
27	Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
28	Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3/NF-B feedback loop. J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. doi: 10.1186/s13046-018-1005-y.
29	Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer. 2006 Sep 1;119(5):1164-75.
30	Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
31	New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids. Arch Toxicol. 2021 Aug;95(8):2691-2718. doi: 10.1007/s00204-021-03092-2. Epub 2021 Jun 20.
32	Zhou-Pan XR, Seree E, Zhou XJ, et al "Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions." Cancer Res 53 (1993): 5121-6. [PMID: 8221648]
33	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
35	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
36	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
37	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
38	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
39	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
40	Cerner Multum, Inc. "Australian Product Information.".
41	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
43	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
44	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
45	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
46	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]